This substantial amendment primarily involves- 1. Addition of a new subject withdrawal criteria related to pancreatitis. 2.Update of one inclusion and two exclusion criteria. 3.Specification of the frequency of Safety Monitoring Board meetings. 4.Addition of new language to the Informed Consent as agreed with USFDA. In addition to the above, a few minor inconsistencies and clarifications are necessary to make the protocol complete, accurate and more informative. Those have also been included.

This substantial amendment involves the addition of text related to liraglutide toxicology results and results in the addition of approved text to the protocol in order to be aligned with the text previously added to the informed consent as requested by the FDA.

This substantial amendment primarily involves : 1.Expansion (widening) of the HBA1C inclusion criteria (to ≥ 6.5% and ≤ 11.0%). 2.Expansion (widening) of the FPG randomisation criterion [ to 110-240 mg/dL, (6.1-13.3 mmol/L). 3.Altering the language of exclusion criterion involving subjects on prior use of antidiabetic treatment. 4. Altering the pharmacokinetic (blood) sampling schedule. 5. Replacement of measurement of CGRP in this study with CEA. 6.Addition of new and updated language and safety information to the protocol and Informed Consent as agreed with the regulatrory authorities. (or approved product labelling). 7.Allowance for protocol to incorporate an IV/IWRS system for drug distribution. 8. Minor changes, clarifications and corrections to several sections for making the protocol clear for execution.

In this substantial protocol amendment- 1. It was clarified that a calcitonin level was obtained at Visit 1, Screening, (and not at Visit 2, Randomisation) in order to be avialable for eligibility evaluation, and at Visit 7 in Part I,for paediatric subjects. 2. It was clarified that a calcitonin level was obtained at Visit 1, Screening (and not a Visit 2 Randomisation),to be available for eligibility evaluation and at Visit 6 in part II for paediatric subjects. 3. A calcitonin level for adult subjects will be obtained at Visit 1, Screening (and not at Visit 2 Randomisation ) to be available for eligibility evaluation, and at Visit 6 in Part II. 4.The calcitonin level in Exclusion Criteria number 22 was changed from ≥ 100ng/L to ›50 ng/L. 5.A review of withdrawal criteria was added to Visits 7 and 8 in Part I and to Visits 6 and 7 in Part II. 6.A check of vital signs was added to the Flow Chart, Part I day 35, Visit 6. 7.It was clarified that body temperature will be recorded in°F or °C. 8.°F as representing degrees Fahrenheit or °C as representing degrees Celsius were added to the List of Abbreviations.

This amendment was implemented in order to add Belgium as a participating country in this trial. The language of the protocol and subject informed consent form was modified accordingly. A minor inconsistency was corrected, allowing for greater accuracy.

The amendment was implemented in order to eliminate the part II of the trial, as per Novo Nordisk's agreement with PDCO on 3 May 2011 (Part II was to evaluate the dose range of 0.6 to 1.8mg liraglutide in paediatric subjects and also included a comparative adult group). In addition , minor inconsistencies were corrected in order to allow for greater accuracy. Justification for the date entered- The amendment date -31Oct 2011 entered showed a validation error , hence the date has been entered as 30 Sep 2011, to surpass the validation error. The date entered here is global end of the trial date. The actual amendment date is 31 Oct 2011.